Sangamo Therapeutics
Update in progressSGMO (PNK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Sangamo Therapeutics is a clinical-stage genomic medicine company translating science into medicines for serious diseases. Its candidates include ST-920 (Phase 1/2) for Fabry disease, small fiber neuropathy, and prion disease; TX200 cell therapy (Phase 1/2) for kidney transplant patients; SB-525 (Phase 3) for hemophilia A; and giroctocogene fitelparvovec (Phase 3) for hemophilia A. It partners with Genentech, Astellas, Eli Lilly, Alexion, Takeda, and others. Formerly Sangamo BioSciences; renamed 2017.
Company score
- Sentiment
- -0.48
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.04
- Governance
- -0.41
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.29
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketPNK
- LocationUnited States
- CEODr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
- Founded1995
- Employees142
- Websitewww.sangamo.com
Identifiers
- ISINUS8006771062
- FIGIBBG000BHYT80
- LEI2549006WMRKRC4G32Z67
- CUSIP800677106
- CIK0001001233